Background and Aims: Cardiovascular diseases remain a leading cause of
mortality worldwide, with dyslipidemia as a significant risk factor. Statins are the
cornerstone of dyslipidemia management; however, statin intolerance presents a
significant barrier in a subset of patients. Some non-statin injectable therapies
come with a relatively prohibitive cost. Bempedoic acid, a novel lipid-lowering
agent that inhibit ATP citrate lyase, has emerged as a potential alternative. This
position statement from the Egyptian Association for Vascular Biology and
Atherosclerosis (EAVA) evaluates the efficacy and safety of Bempedoic acid in
the context of statin intolerance
Methods: An extensive review of current literature, including the CLEAR OUTCOMES
trial, was undertaken. The studies' methodology, patient demographics,
efficacy outcomes, and safety data were critically analyzed. The focus was on
evaluating Bempedoic acid's role in managing dyslipidemia in statin-intolerant
patients, considering both lipid profile improvements and cardiovascular risk
reduction.
Results: This is a position statement of the Egyptian Association of Vascular
biology and Atherosclerosis ( EAVA), on the use of Bempedoic acid in clinical
practice , including indications and recommendations.
Conclusions: Bempedoic acid is an effective and safe LDL-C-lowering therapy in
statin-intolerant patients with and without ASCVD. Bempedoic acid should be
considered for all statin-intolerant patients at high risk of cardiovascular events
(CVEs). It may be also considered for statin-intolerant patients at lower risk of
CVEs who are unable to achieve their LDL-C goals with other lipid-lowering
therapies. Further long-term studies are warranted to establish its role in broader
patient populations and to assess its long-term safety and efficacy